Document is current
Any future updates will be listed below
-
Authors
Kawai, Koichi
Eiki, Jun-ichi https://orcid.org/0000-0002-1622-6114
Kanatsuka, Azuma https://orcid.org/0000-0002-6363-7282
Motohashi, Shinobu
Wakana, Akira
Hayashi, Ai
Iglay, Kristy
Yamazaki, Katsuya
Tokita, Shigeru https://orcid.org/0000-0003-0916-2199
Maegawa, Hiroshi https://orcid.org/0000-0002-4611-8149
,
-
Funding
Funding for this research was provided by:
MSD K.K.
- License Information
-
More Information
Article History
Received: 22 March 2021
Accepted: 20 May 2021
First Online: 15 July 2021
Change Date: 22 July 2021
Change Type: Update
Change Details: The wrong Supplementary file was originally published with this article and it has now been replaced with the correct file.
Declarations
:
: Koichi Kawai., Azuma Kanatsuka., Shinobu Motohashi, and Katsuya Yamazaki have no potential conflicts of interest to declare. Hiroshi Maegawa has received lecture fees from MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Sanofi K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K. Sumitomo Dainippon Pharma Co. Ltd., and Astra Zeneca K.K.; research supports from Astellas Pharma Inc., Astra Zeneca K.K., Nippon Boehringer Ingelheim Co. Ltd., Sunstar Inc., Mitsubishi Tanabe Pharma Corporation, Kyowa Hakko Kirin Co. Ltd., Nissan Chemical Corporation and MIKI Corporation; grants from Takeda Pharmaceutical Co. Ltd., Astellas Pharma Inc., MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Taisho Pharma Co. Ltd., Kowa Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Sanofi K.K., Mitsubishi Tanabe Pharma Corporation, Sanwa Kagaku Kenkyusho Co. Ltd., Eli Lilly Japan K.K., Sumitomo Dainippon Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Bayer Yakuhin Ltd., Teijin Pharma Limited, Shionogi & Co. Ltd.,, Novartis Pharma K.K. and Nipro Corporation. Jun-ichi Eiki, Akira Wakana, Ai Hayashi, Kristy Iglay and Shigeru Tokita are current or former employees of MSD K.K., Tokyo, Japan or Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and may own stock and/or hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA.
